Canada Seeks To Disclose Drug Applicants Under Transparency Drive
Health Canada is seeking feedback on five transparency proposals that include publishing the names of sponsors whose prescription drugs containing new active substances are under review, and making information on generic drug submissions public for the first time.
You may also be interested in...
Health Canada is making its decision-making process in the pre-market phase more transparent by disclosing a wider range of information on new and generic drug applications accepted for review.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.